Viewray Inc to Post FY2019 Earnings of $0.31 Per Share, Zacks Investment Research Forecasts (VRAY)
Viewray Inc (NASDAQ:VRAY) – Equities researchers at Zacks Investment Research upped their FY2019 earnings per share (EPS) estimates for shares of Viewray in a report released on Tuesday. Zacks Investment Research analyst A. Dushyanth now expects that the company will earn $0.31 per share for the year, up from their prior estimate of $0.29.
A number of other analysts also recently commented on VRAY. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Mizuho restated a “buy” rating and set a $12.00 price target on shares of Viewray in a research report on Tuesday, September 26th. Northland Securities restated a “buy” rating and set a $10.00 price target on shares of Viewray in a research report on Friday, November 17th. BidaskClub downgraded shares of Viewray from a “buy” rating to a “hold” rating in a research report on Saturday, December 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Viewray in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.20.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million for the quarter, compared to analysts’ expectations of $18.63 million. The business’s quarterly revenue was up 2950.0% compared to the same quarter last year.
Hedge funds have recently added to or reduced their stakes in the business. Nationwide Fund Advisors raised its position in shares of Viewray by 843.2% during the 2nd quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after buying an additional 14,789 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Viewray by 5.0% during the 2nd quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after buying an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Viewray during the 2nd quarter worth about $159,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of Viewray during the 3rd quarter worth about $164,000. Finally, Citadel Advisors LLC bought a new stake in shares of Viewray in the 3rd quarter worth approximately $174,000. Institutional investors own 50.02% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/01/18/viewray-inc-to-post-fy2019-earnings-of-0-31-per-share-zacks-investment-research-forecasts-vray.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.